How to cite item

Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma

  
@article{CJCR8052,
	author = {Bo Jia and Yuankai Shi and Suyi Kang and Sheng Yang and Shaoxuan Hu and Yexiong Li and Mei Dong and Weihu Wang and Jianliang Yang and Liqiang Zhou and Peng Liu and Shengyu Zhou and Yan Qin and Lin Gui and Changgong Zhang and Hua Lin and Shanshan Chen and Lin Wang and Xiaohui He},
	title = {Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma},
	journal = {Chinese Journal of Cancer Research},
	volume = {27},
	number = {5},
	year = {2015},
	keywords = {},
	abstract = {Background: The role of rituximab in combination with CHOP regimen in patients with stage I diffuse large B-cell lymphoma (DLBCL) remains to be defined. We aimed to compare CHOP plus rituximab (R-CHOP) with CHOP alone and determine the value of radiotherapy in these patients.
Methods: Between 2003 and 2009, 140 untreated patients with stage I DLBCL were retrospectively analyzed in this study.
Results: Seventy-eight patients were treated in R-CHOP group and 62 in CHOP group. Ninety-one patients received additional radiotherapy at the end of chemotherapy. The different treatment groups were well-balanced with respect to baseline characteristics. Complete response (CR) rate was 77% both in R-CHOP and CHOP groups (P=0.945). After a median follow-up period of 56 months, patients received R-CHOP regimen had similar 5-year progression-free survival (PFS) (76% vs. 85%; log-rank P=0.215) and 5-year overall survival (OS) (90% vs. 96%; log-rank P=0.175) compared with those with CHOP alone. Patients with radiotherapy had significantly increased 5-year PFS compared with those who had chemotherapy alone (86% vs. 71%; log-rank P=0.005). At multivariate analysis, patients who had CR (P=0.008) and received radiotherapy (P=0.003) were significantly associated with superior PFS.
Conclusions: CHOP alone could be as effective as R-CHOP regimen and additional radiotherapy would be necessary for stage I or stage I non-bulky DLBCL patients.},
	issn = {1993-0631},	url = {https://cjcr.amegroups.org/article/view/8052}
}